Sysmex (OTCMKTS:SSMXY) Reaches New 12-Month Low - Here's What Happened

Sysmex Corporation ADR (OTCMKTS:SSMXY - Get Free Report) reached a new 52-week low during trading on Tuesday . The company traded as low as $8.15 and last traded at $8.15, with a volume of 294823 shares trading hands. The stock had previously closed at $8.69.Analyst Upgrades and DowngradesSeparately, Citigroup lowered Sysmex from a "strong-buy" rating to a "hold" rating in a research report on Monday, March 16th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold".Get Our Latest Research Report on SSMXYSysmex Price PerformanceThe company has a market capitalization of $5.13 billion, a price-to-earnings ratio of 16.98 and a beta of 1.13. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.44 and a current ratio of 3.33. The business has a 50 day moving average price of $8.82 and a 200-day moving average price of $9.67. Sysmex (OTCMKTS:SSMXY - Get Free Report) last announced its quarterly earnings data on Thursday, February 12th. The company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. The company had revenue of $837.32 million for the quarter, compared to the consensus estimate of $819.99 million. Sysmex had a return on equity of 9.27% and a net margin of 8.86%. Research analysts predict that Sysmex Corporation ADR will post 0.44 EPS for the current fiscal year. Sysmex Company Profile (Get Free Report)Sysmex Corporation OTCMKTS: SSMXY is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex's product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics. The company's core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.Further ReadingFive stocks we like better than SysmexThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Sysmex Right Now?Before you consider Sysmex, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sysmex wasn't on the list.While Sysmex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here